12/18
08:07 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $79.00 to $46.00. They now have a "buy" rating on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $79.00 to $46.00. They now have a "buy" rating on the stock.
12/16
08:07 am
fdmt
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS [Yahoo! Finance]
Low
Report
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS [Yahoo! Finance]
12/16
08:00 am
fdmt
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
Low
Report
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
11/26
07:01 am
fdmt
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
Low
Report
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
11/21
07:40 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
11/14
05:25 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
11/14
01:34 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
11/14
12:07 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $40.00 to $39.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $40.00 to $39.00. They now have an "outperform" rating on the stock.
11/14
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
Low
Report
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
11/13
04:05 pm
fdmt
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Medium
Report
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
11/4
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation
11/3
11:00 am
fdmt
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Low
Report
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
11/2
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
10/31
11:00 am
fdmt
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Low
Report
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/30
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
10/29
11:00 am
fdmt
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Low
Report
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/28
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part
10/27
11:00 am
fdmt
Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Medium
Report
Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/26
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
Medium
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
10/25
11:00 am
fdmt
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Medium
Report
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/24
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
10/23
11:00 am
fdmt
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Medium
Report
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/22
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
10/21
11:00 am
fdmt
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Low
Report
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/20
11:00 am
fdmt
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part
Low
Report
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part